Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia [NA]

View source ↗

Summary

A clinical trial entry for JY231 injection in relapsed or refractory B-cell acute lymphoblastic leukemia, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• JY231

Snippet

Sponsor: He Huang | Conditions: B-ALL | NA | Status: NOT_YET_RECRUITING